Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 41 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2009 First Published: 2/20/2004


1.		Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 69				NCI				NCCTG-N0147 ECOG-N0147, N0147, NCT00079274

Last Modified: 1/29/2009 First Published: 9/16/2005


2.		Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer and at High Risk for Recurrence Based on Molecular Markers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E5202 E5202, NCT00217737

Last Modified: 1/29/2009 First Published: 12/9/2005


3.		Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-C80405 C80405, SWOG-C80405, NCT00265850

Last Modified: 12/13/2008 First Published: 2/17/2006


4.		Phase I/II Study of Dose-Dense and Dose-Intense Capecitabine in Combination With Alternating Full-Dose Irinotecan Hydrochloride and Oxaliplatin With or Without Bevacizumab in Patients With Metastatic or Locally Advanced Unresectable Colorectal Cancer or Other Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				CASE-1205 NCI-7325, 7325, NCT00296062

Last Modified: 1/22/2009 First Published: 10/24/2006


5.		Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				VU-VICC-GI-0622 VICC-GI-0622, 6980, NCI-6980, NCT00397384

Last Modified: 1/9/2009 First Published: 9/16/2008


6.		Phase I/II Randomized Study of Erlotinib Hydrochloride in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci in Patients With Curatively Treated Stage I-III Colorectal Cancer or Adenoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UCIRVINE-UCI06-8-01 UCI06-8-01, NCT00754494

First Published: 12/15/2008


7.		Phase I/II Study of Nonmyeloablative Lymphodepleting Conditioning Comprising Cyclophosphamide and Fludarabine Phosphate Followed by Anti-CEA TCR-Gene Engineered Autologous Lymphocytes and High-Dose Aldesleukin in Patients With Metastatic Cancer That Expresses CEA

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-09-C-0047 09-C-0047, NCI-P08404, NCT00809978

Last Modified: 10/6/2008 First Published: 10/25/2004


8.		Phase II Study of Intrahepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion in Patients With Unresectable Primary or Metastatic Liver Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-04-C-0273 NCI-6332, DELCATH-G990039, NCT00096083

Last Modified: 1/24/2009 First Published: 11/22/2004


9.		Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-E4203 E4203, NCT00098787

Last Modified: 11/16/2008 First Published: 1/24/2005


10.		Phase II Randomized Study of Adjuvant Vaccine Therapy Comprising Vaccinia-CEA-MUC-1-TRICOM Vaccine (PANVAC-V) and Fowlpox-CEA-MUC-1-TRICOM Vaccine (PANVAC-F) Administered With Autologous Dendritic Cells or Sargramostim (GM-CSF) in Patients With Completely Resected Hepatic or Pulmonary Metastases Secondary to Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				DUMC-5883-04-6RO NCT00103142

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute